Beqvez (fidanacogene elaparvovec)
pCPA File Number:
22602
Negotiation Status:
Active Negotiation
Indication(s):
Hemophilia B (congenital Factor IX deficiency) in adults (aged 18 years or older), moderately severe to severe, who are negative for neutralizing antibodies to variant AAV serotype Rh74
Sponsor/Manufacturer:
Pfizer Canada ULC
CDA-AMC Project Number:
SG0802-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable